CapitalBio Technology nets over RMB800m in new financing

CapitalBio Technology has recently announced the completion of a new round of equity financing, and the actual amount raised exceeded the planned target of 800 million yuan.
Guangdong Boye Architectural Design Institute led the round, with participation from Sinopec Capital, Meinian Onehealth Healthcare, New Alliance Capital, RedHorse Capital, Jiaxing Qiao Equity Investment Partnership

CapitalBio Technology has recently announced the completion of a new round of equity financing, and the actual amount raised exceeded the planned target of 800 million yuan.

Guangdong Boye Architectural Design Institute led the round, with participation from Sinopec Capital, Meinian Onehealth Healthcare, New Alliance Capital, RedHorse Capital, Jiaxing Qiao Equity Investment Partnership, among others.

Country Garden Venture Capital provided financial advisory services to Guangdong Boye for this investment.

Founded in 2012, CapitalBio Technology is the commercialization platform of the CapitalBio Corporation, aka the National Engineering Research Center for Beijing Biochip Technology. It operates biochips and medical instruments manufacturing and research and development, and marketing and operation centers in Beijing, Shanghai, Chongqing, Chengdu, Dongguan, Hong Kong, and San Diego.

The proceeds will go towards product R&D, biochip production line expansion, product layout in reproductive health, infections, tumors and other areas, sales team bulking up, market promotion and overseas market expansion.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/02/capitalbio-technology-nets-over-rmb800m-in-new-financing/.

Leave a Reply

Your email address will not be published. Required fields are marked *